FDA – Page 2 – media

One Boy’s Struggle with Epilepsy Leads to First Marijuana-Derived Medicine

Epidiolex, compounded from decontaminated cannabidiol, or CBD, permitted for two atypical types of epilepsy, would be the first prescription medication extracted from the marijuana plant, expected to reach pharmacies this fall.
- Source: NPR
- 718
- August 9, 2018
FDA Medical marijuana New Approvals
Alembic Pharma gets USFDA Approval for Ophthalmic Solution

Hypotrichosis is defined as the condition of abnormal hair patterns which leads to predominant loss or reduction. Usually, hair growth is normal after birth, but later, hair starts shedding and is replaced by abnormal hair growth patterns. The new hair will be short and brittle without pigmentation.
- Source: MoneyControl
- 814
- August 8, 2018
FDA Hypotrichosis New Approvals
Sun Pharma Launches Kapspargo Sprinkle to Treat Chest Pain & High Blood Pressure

Sun Pharma, India’s largest drugmaker, has launched Kapspargo Sprinkle in the US. This drug is used in the treatment of heart failure, chest pain, and high blood pressure.
- Source: MoneyControl
- 583
- August 7, 2018
beta blocker FDA New Approvals
Avatrombopag Reduced Procedure-Related Transfusions in Thrombocytopenia, Chronic Liver Disease Patients

Findings from two international, randomized, double-blind, phase III, placebo-controlled trials published in the September issue of Gastroenterology revealed that the oral second-generation thrombopoietin agonist avatrombopag (Doptelet) when given once a day, notably decreased the requirement for platelet transfusion...
- Source: MDEdge
- 934
- August 3, 2018
chronic liver disease Clinical Trials FDA
Adherium Receives FDA Clearance for Hailie Inhaler Sensor

Adherium, the makers of inhaler sensors, has received 510(k) US-FDA clearance for the sales of its Hailie sensor, previously known as Smartinhaler. The individual versions of this device were previously cleared for use with the asthma inhalers like Ventolin HFA, ProAir HFA, and Flovent HFA.
- Source: MobiHealthNews
- 1,261
- August 1, 2018
asthma FDA New Approvals
FDA Warns of Unapproved Vaginal ‘Rejuvenation’ Procedures

The US-FDA has warned against medical device manufacturers for developing cosmetic vaginal rejuvenation procedures to treat vaginal atrophy, laxity, itching/dryness, pain during sex or urination and reduced sexual sensation.
- Source: Medpagetoday
- 856
- August 1, 2018
FDA Policies
Endomag Breast Cancer Device Gains FDA Approval

Endomag received premarket approval from the FDA for Magtrace, the novel non-radioactive dual-tracer for lymphatic plotting in breast cancer patients which facilitates the implementation of magnetic detection during sentinel lymph node biopsy procedures to spot sentinel lymph nodes for surgical excision.
- Source: The Verdict
- 786
- August 1, 2018
cancer FDA medical device New Approvals
NuVasive gets FDA Approval for Pulse Spinal Surgical Automation Platform

The San Diego-based company NuVasive has announced US-FDA 510(k) clearance for its Pulse spinal surgical automation platform. The platform includes 2D and 3D navigation and smart imaging capabilities, with implemented surgical planning, neuromonitoring, patient-specific rod bending tech and radiation reduction.
- Source: MassDevice
- 193
- July 31, 2018
FDA medical device New Approvals
Contamination of Synthetic Cannabis with Rat Poison Affects Blood Supply

Various synthetic cannabis products such as “spice” and K2 have been contaminated with a rat poison ingredient that affects the blood supply. Hundreds of people in 10 states in the USA have been diagnosed with symptoms like seizures and severe bleeding after using these products, as declared by US-FDA.
- Source: NBC News
- 855
- July 30, 2018
FDA Policies
Monoclonal Antibody Delays Cognitive Decline, Erases Alzheimer’s Plaques in Phase 2 Trial

A phase 2 study on BAN2401, a monoclonal antibody that hits soluble amyloid beta oligomers, showed that it limits cognitive decline in patients with slight cognitive injury or premature Alzheimer’s dementia on two scales and removed brain amyloid in 81% of patients in the trial.
- Source: MDEdge
- 956
- July 30, 2018
Alzheimer's disease Clinical Trials FDA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.